Evidence map›Paper›PMID 34725853›Full record

ArticleStatistics in medicine2022

Limitations of clinical trial sample size estimate by subtraction of two measurements.

Kewei Chen, Xiaojuan Guo, Rong Pan, Chengjie Xiong, Danielle J Harvey, Yinghua Chen, Li Yao, Yi Su, Eric M Reiman, Alzheimer's Disease Neuroimaging Initiative

Abstract read
In one paragraph

Article in Statistics in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Sample size determination for a study with variable follow-up time.Journal of biopharmaceutical statistics · 2025
    Article
  2. Contributions of the ADNI Biostatistics Core.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kewei ChenBanner Alzheimer's Institute, Phoenix, Arizona, USA.ORCID 0000-0001-8497-3069
Xiaojuan GuoArizona Alzheimer's Consortium, Phoenix, Arizona, USA.
Rong PanDepartment of Mathematics and Statistics, Arizona State University, Tempe, Arizona, USA.ORCID 0000-0001-5171-8248
Chengjie XiongBeijing Key Laboratory of Brain Imaging and Connectomics, Beijing Normal University, Beijing, China.
Danielle J HarveyDivision of Biostatistics, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Yinghua ChenBanner Alzheimer's Institute, Phoenix, Arizona, USA.
Li YaoArizona Alzheimer's Consortium, Phoenix, Arizona, USA.
Yi SuBanner Alzheimer's Institute, Phoenix, Arizona, USA.
Eric M ReimanBanner Alzheimer's Institute, Phoenix, Arizona, USA.
Alzheimer's Disease Neuroimaging Initiative

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI Duygu Tosun-Turgut · 2016 to 2026
$226.7M
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Alzheimer's Prevention Initiative APOE4 TrialUF1AG046150 · NIA · BANNER ALZHEIMER'S INSTITUTE · PI REIMAN, ERIC MICHAEL, TARIOT, PIERRE N. · 2013 to 2013
$33.3M
Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI REIMAN, ERIC MICHAEL · 2001 to 2020
$32.5M
APOE in the Predisposition to, Protection from and Prevention of Alzheimer's DiseaseR01AG069453 · NIA · BANNER HEALTH · PI ASHTON, NICHOLAS, LANGBAUM, JESSICA BROOKE · 2020 to 2025
$27.4M
Research Education ComponentP30AG072980 · NIA · BANNER HEALTH · PI Nicholas Ashton · 2021 to 2026
$24.9M
PET, APOE & the Preclinical Course of Alzheimer's DiseaseR01AG031581 · NIA · BANNER ALZHEIMER'S INSTITUTE · PI CASELLI, RICHARD J., REIMAN, ERIC MICHAEL · 2008 to 2018
$16.6M
Alzheimer's Prevention InitiativeRF1AG041705 · NIA · BANNER ALZHEIMER'S INSTITUTE · PI LOPERA, FRANCISCO, REIMAN, ERIC MICHAEL · 2012 to 2012
$15.3M
PET, APOE, &THE PRECLINICAL COURSE OF ALZHEIMER DISEASER01MH057899 · NIMH · BANNER GOOD SAMARITAN MEDICAL CENTER · PI REIMAN, ERIC MICHAEL · 1998 to 2006
$5.2M
NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG072980NIA NIH HHS R01 AG031581NIA NIH HHS R01 AG069453NIA NIH HHS RF1 AG041705NIA NIH HHS U01 AG024904NIA NIH HHS U19 AG024904NIA NIH HHS UF1 AG046150NIMH NIH HHS R01 MH057899
6 · The paper itself

Abstract

In planning randomized clinical trials (RCTs) for diseases such as Alzheimer's disease (AD), researchers frequently rely on the use of existing data obtained from only two time points to estimate sample size via the subtraction of baseline from follow-up measurements in each subject. However, the inadequacy of this method has not been reported. The aim of this study is to discuss the limitation of sample size estimation based on the subtraction of available data from only two time points for RCTs. Mathematical equations are derived to demonstrate the condition under which the obtained data pairs with variable time intervals could be used to adequately estimate sample size. The MRI-based hippocampal volume measurements from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and Monte Carlo simulations (MCS) were used to illustrate the existing bias and variability of estimates. MCS results support the theoretically derived condition under which the subtraction approach may work. MCS also show the systematically under- or over-estimated sample sizes by up to 32.27

Indexed as

Alzheimer DiseaseHumansMagnetic Resonance ImagingNeuroimagingResearch DesignSample Sizelinear mixed effects modelrandomized clinical trialsample size estimationsubtractiontwo time point measurement

Identifiers

PMID34725853
PMCPMC8916961

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.